



Welsh Cardiovascular Society
Cymdeithas Cardiofasciwlar Cymru

Spring Meeting, Hybrid Platform. **Raddison Blu Hotel (Cardiff) + Virtual Platform**

Thursday, May 5th 2022

08.30-10.30: STC meeting
Claire Williams

10.30-11.00: Coffee

11.00-13.00: Mitral valve Intervention

- 11.00-11.15 Assessing the MV with TTE - Nav Masani
- 11.15-11.35 Assessing the MV with TOE & suitability for Mitraclip - Richard Wheeler
- 11.35-11.50 Doing a Mitraclip procedure - Richard Anderson
- 11.50-12.05 Referral pathways and case examples from Cardiff - Andrew Sharp + team
- 12.05-12.15 Discussion

○ 12.15-12.45 Current options and future horizons (virtual presentation)

Dr Azeem Latib, Director of Structural Heart Interventions, Montefiore Medical Centre, New York.

○ 12.45 Q&A

13.00-14.00: Lunch

14.00-16.00: SGLT-2 inhibitors

- 14.00-14.40 Geraint Jenkins: SGLT-2 inhibitors in HFREF and HFPEF
- 14.40-15.20 Jeff Stevens: SGLT-2 inhibitors in diabetes and patients with high CV risk
- 15.20-16.00 Alexa Wonnacott: SGLT-2 inhibitors in chronic kidney disease

16.00-17.00: The Henderson Lecture

Professor Douglas Chamberlain

17.00-18.00: BCS Centenary lecture (virtual presentation)

Professor Barbara Casadei

18.00-19.30: Drinks Reception: Radisson Blu

20.00: Welsh Cardiovascular Society annual dinner: Raddison Blu

Friday, May 6th 2022

9.30-10.00: President's Address
Phil Avery

10.30-12.00: Business Issues

STC update: Claire Williams

Network Update: Jonathan Goodfellow

Regional Updates: All

12.00: Meeting end with lunch

The following companies are exhibiting at this meeting:

Abbott Vascular, Amarin, Amgen, Astra Zeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Daiichi Sankyo, Novartis, Pfizer.